Claire Bennett had given this demo eleven times. She could do it with a migraine and a dead phone and a hangover, and twice she'd done it with all three.
Today the room was the Meridian Room at Boston Medical Tech's Seaport headquarters. Floor-to-ceiling glass on one side, harbor marbled gray beyond it, a conference table the exact shade of a well-heeled balance sheet. Twelve chairs, eleven filled. The twelfth held the only person Claire actually needed to convince: Marcus Osei, managing partner at Halcyon Ventures, who had flown in from Menlo Park on the strength of a single leaked whitepaper and had not yet stopped checking his phone.
Claire clicked the remote. The screen bloomed into the CardioSense dashboard—dark navy, humane typeface, a floating heart rendered in soft gradient, its chambers pulsing in time with a simulated beat.
"Every forty seconds, a woman in the United States has a heart attack," she said. "Between one in eight and one in ten of them will be sent home from an emergency department with a diagnosis of anxiety, indigestion, or stress. CardioSense exists to end that."
She let the number sit. Osei looked up.
"Walk me through the mechanism," he said.
"Pass."
The demo patient loaded—female, fifty-eight, chest tightness, fatigue, jaw pain. Claire advanced the timeline four clinical steps. On the screen, the algorithm's confidence bar filled: 0.94, Myocardial infarction, anterior. Recommend immediate troponin panel and cardiac catheterization.
"From first ECG to flagging: eleven seconds. Our validation cohort is ninety-four thousand encounters across six health systems. Sensitivity ninety-six point two. Specificity ninety-three point eight." She clicked to the results table, let it hold. "We've never missed an anterior MI in the validation set. Not once."
"Athena Health Partners goes live in six weeks," said Daniel Reyes, BMC's CEO, from the head of the table, with the satisfied air of a man narrating his own biography. "CardioSense will be in four hundred and twelve emergency departments by Q3. And we are looking for the right partner to scale that further."
It was, Claire thought, a beautiful machine. She had spent three years of her life inside it—three years of nights in the lab with the clinical team, of scrubbing false positives out of the training set, of arguing about priors until she'd lost her voice. She had signed off on the validation. She had, in effect, given it a heartbeat.
Osei leaned in. "You've got an FDA clearance and a competitor nipping at your clearance. Why do I believe the moat is real?"
"Because our competitor trained on claims data," Claire said. "We trained on waveforms. A claims model knows what was coded. Ours knows what the heart was doing."
That got a smile. His first.
The double doors at the back of the room opened.
"Excuse me."
The woman couldn't have been much past sixty, in a wool coat too heavy for September and shoes that had been walked in hard. She held a manila folder to her chest the way you hold something breakable.
"Ma'am, we're in a closed session—" Daniel began, already half rising, already gesturing to no one in particular for security.
"My name is Maria Alvarez." Her voice had a slight tremor in it, but she looked directly at Claire, not at Daniel, not at the eleven afternoon investors in the room. "I'm here about your algorithm. It killed my sister."
The room went still in the particular way rooms go still when someone says a dangerous, unverifiable thing in front of people who write checks.
"Mrs. Alvarez," Daniel said. "I'm so sorry for your loss. Truly. But this is not—"
"Yolanda Reyes. Fifty-four." The woman opened the folder. Photocopied pages fanned out; she didn't hand them over, only held them up, a shield and a weapon. "Two years ago she went to her hospital with shoulder pain, nausea, and exhaustion. She was told it was a virus. She was sent home. She died of a heart attack eleven hours later in her own kitchen."
Claire's mouth had gone dry. "That's a real tragedy. But CardioSense wasn't deployed at that hospital. We're not in general release yet—"
"I know it wasn't. It's what I'm afraid of." Maria stepped forward anyway; Daniel reached her first, gentle and firm, trying to steer her toward the door. She didn't fight him. She just kept talking, pitched at Claire across the conference table like a note passed in class. "Your algorithm looks for chest pain first. But two-thirds of women present without it. Fatigue. Nausea. Jaw. Back. Your system ranks those lower. Every single time."
"That's not—" Claire stopped herself. Because she didn't know that. She knew the validation numbers, top-line, aggregate. She did not know, right at this moment, on her feet, in front of Osei, whether the feature weighting on atypical presentations was what it ought to be.
"Mrs. Alvarez, we'll take your materials," Claire said. "I'll look into it personally."
"You'll look into it." Maria's face folded—not angry, worse than angry. Tired. "You know what I already sent? Three emails to that generic contact address on your website. Two phone calls. I have a case number. It's been a hundred and forty days."
Daniel had her at the door now. "Thank you for coming in. We'll follow up through the proper channels."
"Make it a priority," Claire said, and heard how thin it sounded.
The doors closed. Daniel smoothed his jacket, returned to his chair, and said, with the effortless pivot of a man who had raised five rounds, "Fifteen years ago every one of us was talking about a screening test that had a real-world gap in Black patients. Different company, different era—and they handled it publicly, which is why they're still standing. What you just saw is exactly why this product matters. We'll be back in touch this week."
Osei was looking at the door, not at Daniel. He was looking at the door for a long moment, and Claire could not read it: the softness of a man moved, or the wariness of a man who had just watched an unvetted citizen walk into a due diligence room and attach the word *killed* to the product.
"Thank you," he said, finally, to the room in general.
Daniel found her twenty minutes later in the corridor by the elevator bank, where the harbor showed through the glass in wide, indifferent slabs.
"First thing," he said. "You did not promise that woman anything."
"I said I'd look into it."
"That's the same thing, Claire, in the version of reality her lawyer eventually gets to read." He kept his voice low and pleasant. Two analysts were walking past; Daniel smiled at them until they were gone. "This is a pre-launch period. We have a clearance, we have a term sheet pending, and we have a competitor who is praying every night that someone at this company says the wrong sentence to the wrong reporter."
"Daniel, she sent emails. A hundred and forty days."
"And if she sent them to a general inbox, that's an operations gap, which I'll own. Not a product gap." He looked at her with something that wanted very hard to read as warmth. "For three years you have been the most rigorous person in this building. That's why you're the one standing in the Meridian Room. So be rigorous now: don't debug the product because someone was moved and a venture capitalist was in the room. Handle it quietly. Make her go away—kindly. Say whatever you need to say to make her feel heard, and then route it to Legal and let them handle the letter."
"Handle it *quietly*."
"Discreetly." He tapped the elevator call button for her. "There's a difference. Don't make it a headline and I'll consider this closed."
The doors opened. He stepped in, already thumbing his phone, already elsewhere.
Claire took the stairs down four flights because she wanted the echo, and ended up in her corner of the eighth floor with the lights mostly off. The clinical team had gone home.
She sat down and opened the validation package she had personally signed off on. Ninety-four thousand encounters. She had reviewed the summary tables. She had not, she realized now, with a coldness that began in her sternum and moved outward, ever pulled the subgroup breakdown by presentation type.
She filtered it. Atypical presentations—women, majority of them—nausea, fatigue, jaw, back. No chest pain. She pulled the sensitivity figure, expecting 0.93. Something to screenshot and wave at Maria Alvarez, kindly, with the proper channels attached.
0.71.
Claire sat back.
She checked it against the inclusion criteria. Then against the confidence thresholds. She went back into her own memory of the design reviews and found that she couldn't place the number. Not once. It had never been in a single deck she'd shown. It had never been in the deck she'd shown an hour ago.
The floating heart on her dark screen kept its serene pulse, 0.94, so confident, so certain. Eleven seconds to save a life. And a fifty-four-year-old woman with shoulder pain and nausea, waiting in an ER at two in the morning, who did not present like the training data's idea of a heart attack—whom the model would rate, quietly, two chances in three.
She opened Maria Alvarez's folder, which the woman had pressed into her hands on her way out the door, and read the hospital records slowly, twice, in the dark.
Then she picked up her phone and did not call Daniel, and did not call Legal, and she did not know yet what she did instead.